Referenser
1) Alonso J et al. European Study of the Epidemiology of Mental Disorders (ESEMeD)
Project Prevalence of mental disorders in Europe: results from the European Study of the
Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004;109
(Suppl. 420):21–27.
2) Alonso J et al. European Study of the Epidemiology of Mental Disorders (ESEMeD)
Project Disability and quality of life impact of mental disorders in Europe: results from
the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta
Psychiatr Scand 2004;109 (Suppl. 420):38–46.
3) Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Duration of major
depressive episodes in the general population: results from The Netherlands Mental
Health Survey and Incidence Study (NEMESIS). Br J Psychiatry. 2002 Sep;181:208-13.
4) Keller MB, Boland RJ. Implications of failing to achieve successful longterm maintenance
treatment of recurrent unipolar major depression. Biol Psychiatry 1998;44:348–
360.
5) Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen
Psychiatry 1997;54:989–991.
6) Zis AP, Goodwin FK. Major affective disorders as a recurrent illness: a critical
review. Arch Gen Psychiatry 1979;36:835–839.
7) Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008 Oct
16;455(7215):894-902.
8) Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry.
1991 Jun;52 Suppl:4-10.
9) Drevets W C. Prefrontal cortical-amygdala metabolism in major depression. Ann N Y
Acad Sci 1999;877: 614–637.
10) Mayberg H S, Liotti M, Brannan S K, McGinnis B S, Mahurin R K, Jerabek P A,
Silva J A, Tekell J L, Martin C C, Lancaster J L, Fox P T. Reciprocal limbic-cortical
function and negative mood: converging PET findings in depression and normal sadness.
Am J Psychiatry 1999;156: 675–682.
11) Davidson J R, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission
with venlafaxine and fluoxetine in major depression its relationship to anxiety symptoms.
Depress Anxiety 2002;16: 4–13.
12) Drevets W C, Bogers W, Raichle M E. Functional anatomical correlates of antidepressant
drug treatment assessed using PET measures of regional glucose metabolism.
Eur Neuropsychopharmacol 2002;12: 527–544.
13) Liotti M, Mayberg H S, McGinnis S, Brannan S L, Jerabek P. Unmasking diseasespecifi
c cerebral blood flow abnormalities: mood challenge in patients with remitted
unipolar depression. Am J Psychiatry 2002;159: 1830–1840.
14) Levesque M, Bedard A, Cossette M, Parent A. Novel aspects of the chemical anatomy
of the striatum and its efferents projections. J Chem Neuroanat 2003;26: 271–281.
15) Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, Carrasco
JL,Stahl S. The other face of depression, reduced positive affect: the role of catecholamines
in causation and cure. J Psychopharmacol. 2007 Jul;21(5):461-71.
16) Gorwood P. Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci.
2008;10(3):291-9.
17) Berridge KC. The debate over dopamine’s role in reward: the case for incentive salience.
Psychopharmacology. 2007 Apr;191(3):391-431.
18) Stein DJ. Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic
neurocircuitry. CNS Spectr. 2008 Jul;13(7):561-5.
19) Stahl S M, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in
depression: a novel approach to psychopharmacology of wakefulness, fatigue and
executive dysfunction in major depressive disorder. J Clin Psychiatry 2003;64 (Suppl.
14): 6–17.
20) Drevets W C, Bogers W, Raichle M E. Functional anatomical correlates of antidepressant
drug treatment assessed using PET measures of regional glucose metabolism.
Eur Neuropsychopharmacol 2002;12: 527–544.
21) Bodkin J A, Lasser R A, Wines J D Jr, Gardner D M, Baldessarini R J. Combining
serotonin reuptake inhibitors and voxra in partial responders to antidepressant
monotherapy. J Clin Psychiatry 1997; 58:137–145.
22) Demyttenaere K, Fruyt J, Stahl S M. The many faces of fatigue in major depressive
disorder. Int J Neuropharmacol 2004;8: 93–105.
23) Nierenberg A A, Keefe B R, Leslie V C, Alpert J E, Pava J A, Worthington III J J,
Rosenbaum J F, Fava M. Residual symptoms in depressed patients who respond acutely
to fluoxetine. J Clin Psychiatry 1999; 60: 221–225.
24) Nierenberg A A, DeCocco L M. Definitions of antidepressant treatment response,
remission, non-response, partial response, and other relevant outcomes: a focus on treatment-
resistant depression. J Clin Psychiatry 2001;62 (Suppl. 16): 5–9.
25) Petersen T, Papakostas G I, Pasternak M A, Kant A, Guyker W M, Iosifescu D V,
Yeung A S, Nierenberg A A, Fava M. Empirical testing of two models for staging antidepressant
treatment resistance. J Clin Psychopharmacol 2005;25: 336– 341.
26) Trivedi M H, Rush A J, Wisniewski S R, Warden D, McKinney W, Downing M, Berman
S R, Farabaugh A, Luther J F, Nierenberg A A, Callan J A, Sackeim H A Evaluation
of outcomes with citalopram for depression using measurement-based care in STAR*D:
implications for clinical practice. Am J Psychiatry 2006;163: 28–40.
27) Rush A J, Trivedi M H. Treating depression to remission. Psychiatr Ann 1995;25:
704–709.
28) Thase M E, Entsuah A R, Rudolph R L. Remission rates during treatment with venlafaxine
or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234–241.
29) Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability
of venlafaxine compared with selective serotonin reuptake inhibitors and other
antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396–404.
30) Nierenberg A A, DeCocco L M. Definitions of antidepressant treatment response,
remission, non-response, partial response, and other relevant outcomes: a focus on treatment-
resistant depression. J Clin Psychiatry 2001;62 (Suppl. 16): 5–9.
31) Moos R H, Cronkite R C. Symptom-based predictors of a 10-year chronic course of
treated depression. J Nerv Ment Dis 1999; 187: 360–368.
32) Spijker J, Bijl R V, de Graaf R, Nolen W A. Determinants of poor 1-year outcome
of DSM-III-R major depression in the general population: results of the Netherlands
Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand
2001;103:122–130.
33) Gold P W, Chrousos G P. The endocrinology of melancholic and atypical depression:
relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians
1998;111: 22–34.
34) Schmidt K, Nolte-Zenker B, Patzer J, Bauer M, Schmidt L G, Heinz A. Psychopathological
correlates of reduced dopamine receptor sensitivity in depression, schizophrenia
and opiate and alcohol dependence. Pharmacopsychiatry 2001;34: 66–72.
35) Bremner J D, Abrahams L M, Crupie J E, McCawley A, Proctor R C, Sathananthan
S L. Multicenter double-blind comparison of nomifensine and imipramine for efficacy
and safety in depressed outpatients. J Clin Psychiatry 1984;45: 56–59.
36) Rampello L, Nicoletti G, Raffaele R. Dopaminergic hypothesis for retarded depression:
a symptom profile for predicting therapeutical responses. Acta Psychiatr Scand
1991;84: 552–554.
37) Jamerson B, Krishman K R R, Roberts J, Krishen A, Modell J G. Effect of voxra
SR on specific symptoms clusters of depression: analysis of the 31-item Hamilton
Rating Scale for Depression. Psychopharmacol Bull . 2003;37: 67–78.
38) Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol.
2006 Aug;16(6):391-402.
39) Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman
DS, Modell JG. Extended-release voxra for patients with major depressive
disorder presenting with symptoms of reduced energy, pleasure, and interest: findings
from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006
Jun;67(6):865-73.
40) Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, Carrasco
JL,Stahl S. The other face of depression, reduced positive affect: the role of catecholamines
in causation and cure. J Psychopharmacol. 2007 Jul;21(5):461-71.
41) Voxra produktmonografi. www.fass.se
42) Stahl S M, Pradko J F, Haight B R, Modell J G, Rockett C B, Learned-Coughlin S.
A review of the neuropharmacology of voxra, a dual norepinephrine and dopamine
reuptake inhibitor. Prim Care Companion, J Clin Psychiatry 2004;6:159–166.
43) Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol.
2006 Aug;16(6):391-402.
44) Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry. 2008;69
Suppl E1:8-13.
45) Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-
blind Comparison Between Voxra XL and Venlafaxine XR. Sexual Functioning,
Antidepressant Efficacy, and Tolerability. J Clin Psychopharmacol 2006;26(5):482-488.
46) Croft H, Settle E Jr, Houser T, Batey S R, Donahue R M, Ascher J A. A placebocontrolled
comparison of the antidepressant efficacy and effects on sexual functioning of
sustained-release voxra and sertraline. Clin Ther 1999;21: 643–658.